Profile data is unavailable for this security.
About the company
Marksans Pharma Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The Company produces goods across various therapeutic areas, such as pain management, cough and cold, cardiovascular and central nervous system, anti-diabetic, gastrointestinal, hormonal treatment, and anti-allergic, among others. The Company operates four manufacturing facilities across India, the United Kingdom and the United States. The Company manufactures oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
- Revenue in INR (TTM)21.77bn
- Net income in INR3.14bn
- Incorporated1992
- Employees1.40k
- LocationMarksans Pharma Ltd21 Lotus Business Park, Off New Link Road,, Andheri (W)MUMBAI 400053IndiaIND
- Phone+91 2 240012000
- Fax+91 2 240012099
- Websitehttp://www.marksanspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aarti Drugs Ltd | 25.29bn | 1.71bn | 48.42bn | 1.50k | 28.30 | 3.78 | 21.71 | 1.91 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 54.85bn | 1.63k | 25.28 | 3.12 | 18.90 | 2.96 | 23.94 | 23.94 | 204.48 | 193.88 | 0.7698 | 1.63 | 3.86 | 11,386,720.00 | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.00 | 18.77 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Shilpa Medicare Ltd | 11.51bn | 318.74m | 65.08bn | 1.03k | 180.86 | 3.19 | 46.55 | 5.65 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Orchid Pharma Ltd | 8.19bn | 915.95m | 72.69bn | 838.00 | 74.88 | 6.22 | 56.91 | 8.87 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1036 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Sun Pharma Advanced Research Co Ltd | 755.45m | -3.87bn | 73.56bn | 409.00 | -- | 58.49 | -- | 97.37 | -11.93 | -11.93 | 2.33 | 3.88 | 0.1123 | 22.11 | 2.32 | 1,847,073.00 | -57.57 | -61.70 | -85.94 | -119.31 | 62.76 | 74.49 | -512.56 | -163.40 | 1.01 | -244.66 | 0.3272 | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 77.43bn | -- | 47.27 | 9.16 | 40.36 | 10.88 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| F D C Ltd | 19.43bn | 3.05bn | 81.75bn | 6.37k | 26.98 | 3.90 | 23.70 | 4.21 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 86.88bn | 1.41k | 40.62 | -- | 36.08 | 7.43 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Marksans Pharma Ltd | 21.77bn | 3.14bn | 90.78bn | 1.40k | 28.91 | 4.40 | 23.33 | 4.17 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Strides Pharma Science Ltd | 40.51bn | -1.25bn | 93.90bn | 2.85k | -- | 4.42 | 130.15 | 2.32 | -13.86 | -7.93 | 445.06 | 231.29 | 0.6493 | 1.44 | 3.32 | -- | -2.38 | -1.68 | -4.43 | -2.97 | 59.50 | 52.74 | -3.67 | -3.36 | 0.64 | 1.07 | 0.5485 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 104.23bn | 1.82k | 23.36 | -- | 20.76 | 4.54 | 36.41 | 36.41 | 186.83 | -- | -- | -- | -- | -- | -- | 18.28 | -- | 30.03 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Neuland Laboratories Ltd. | 15.59bn | 3.00bn | 107.48bn | 1.65k | 35.82 | 8.38 | 29.87 | 6.90 | 233.89 | 233.89 | 1,214.81 | 999.78 | 0.9135 | 2.33 | 4.24 | 9,457,406.00 | 17.59 | 9.25 | 23.58 | 12.71 | 52.92 | 47.81 | 19.25 | 11.99 | 1.33 | 28.78 | 0.0692 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 114.73bn | 1.03k | 20.77 | -- | 12.32 | 1.68 | 34.89 | 34.89 | 431.45 | -- | -- | -- | -- | -- | -- | 2.96 | -- | 3.55 | 68.13 | 69.37 | 8.01 | 5.13 | -- | 2.34 | -- | 24.69 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Caplin Point Laboratories Ltd | 16.94bn | 4.57bn | 116.10bn | 777.00 | 25.50 | 5.01 | 22.55 | 6.85 | 59.90 | 59.90 | 222.01 | 304.93 | 0.6931 | 2.22 | 3.62 | -- | 18.88 | 19.83 | 21.80 | 22.82 | 57.25 | 53.99 | 27.24 | 25.39 | 4.63 | 976.47 | 0.0008 | -- | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | -- |
| Wockhardt Ltd | 27.98bn | -4.63bn | 130.90bn | 2.39k | -- | 3.90 | -- | 4.68 | -32.08 | -32.08 | 194.04 | 218.97 | 0.365 | 1.80 | 3.95 | 11,687,550.00 | -6.16 | -4.56 | -11.11 | -8.29 | 58.36 | 55.26 | -16.87 | -12.70 | 0.5532 | -0.1594 | 0.3915 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
Data as of Jul 29 2024. Currency figures normalised to Marksans Pharma Ltd's reporting currency: Indian Rupee INR
5.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Jun 2024 | 9.28m | 2.05% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 4.86m | 1.07% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 2.72m | 0.60% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 1.75m | 0.39% |
| Old Bridge Asset Management Pvt Ltd.as of 30 Jun 2024 | 1.58m | 0.35% |
| Bandhan Asset Management Co. Ltd.as of 30 Jun 2024 | 993.94k | 0.22% |
| Fiduciary Management, Inc.as of 30 Jun 2024 | 662.00k | 0.15% |
| Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2024 | 550.00k | 0.12% |
| Templeton Investment Counsel LLCas of 31 Mar 2024 | 546.83k | 0.12% |
| Mellon Investments Corp.as of 03 Jul 2024 | 440.29k | 0.10% |
More ▼
Data from 31 Mar 2024 - 15 Jul 2024Source: FactSet Research Systems Inc.
